SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of ...
Insulin resistance, or low insulin sensitivity, happens when cells throughout the body don’t respond properly to the hormone insulin, especially cells in: Insulin is a pancreatic hormone that allows ...
On Feb. 14, 2025, the FDA approved Merilog (insulin-aspart-szjj), the first rapid-acting insulin biosimilar to NovoLog (insulin aspart), marking a pivotal moment in diabetes care. The approval is ...
Merilog, a biosimilar to Novolog, offers a more affordable insulin option for type 2 diabetes patients, enhancing treatment accessibility. The GEMELLI-1 trial confirmed Merilog's noninferiority to the ...
Kirsty 100units/mL is supplied as a 3mL single-patient-use prefilled pen as well as a 10mL multiple-dose vial. The approval of insulin aspart-xjhz was supported by a comprehensive data package that ...
The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to enhance glycemic control in adults and children with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results